INTRODUCTION

The COVID-19 lockdown has had pervasive effects on children, including school closures, a shift to remote learning, and suspension of youth sports and recreational activities. Children gain weight at an accelerated rate when not in school (1), which has been attributed to greater engagement in obesogenic behaviors when children’s days are unstructured (2). There is emerging evidence that children’s physical activity, sedentary time, eating patterns, and sleep routines deteriorated during the COVID-19 lockdown (3-7) and that normal-weight children gained weight at an alarming pace (8).

The degree to which the pandemic interfered with weight-management efforts among children with overweight or obesity has not been reported, to our knowledge, to date, particularly in low-income, racially diverse populations. Standard-of-care pediatric weight-management interventions generally produce modest, but sustained and meaningful, reductions in weight (9). However, their efficacy may have been diminished during the COVID-19 lockdown. Understanding the impact of the pandemic on weight-management interventions is important for ongoing treatment planning and for interpreting the results of pediatric obesity treatment trials conducted during this period. This study leveraged data from 230 low-income families participating in a clinical trial to examine the change in efficacy of structured, family-based pediatric obesity treatment delivered before versus during the COVID-19 lockdown.

Attenuated efficacy of pediatric obesity treatment during the COVID-19 pandemic

Bradley M. Appelhans1,2 | Simone A. French3 | Molly A. Martin4 | Karen Lui5 | Imke Janssen1

1Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois, USA
2Department of Psychiatry and Behavioral Sciences, Rush University Medical Center, Chicago, Illinois, USA
3Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
4Department of Pediatrics, University of Illinois at Chicago, Chicago, Illinois, USA
5Department of Pediatrics, Rush University Medical Center, Chicago, Illinois, USA

Correspondence
Bradley M. Appelhans, Department of Preventive Medicine, Rush University Medical Center, 1700 W. Van Buren St., Suite 470, Chicago, IL 60612, USA. Email: brad_appelhans@rush.edu

Funding information
This study was supported by NIH grant R01DK111358. The content is solely the responsibility of the authors and does not necessarily reflect the official views of the NIH.

Abstract

Objective: This study examined whether the efficacy of a standard-of-care pediatric obesity treatment was affected by the COVID-19 pandemic.

Methods: Analyses leveraged data from an ongoing pediatric obesity treatment trial involving 230 lower-income, urban children aged 6 to 12 years. Mixed-effects regression models compared children who participated in a 12-month weight-management intervention before versus during the COVID-19 pandemic on change from baseline in BMI z score (ΔzBMI) at 3, 6, 9, and 12 months.

Results: The observed pattern of ΔzBMI was significantly different before versus during the pandemic ($\chi^2 = 22.73, p < 0.0001$). Children treated before the pandemic maintained an average weight loss of $-0.06 \Delta zBMI$ at 12 months, whereas children treated during the pandemic steadily gained weight over time, averaging a net gain of $0.11 \Delta zBMI$ at 12 months ($\chi^2 = 34.99, p < 0.0001$). Treatment session completion did not differ before versus during the pandemic (60.4% vs. 55.7%, respectively; $p = 0.30$) or account for differences in ΔzBMI.

Conclusions: Similar reductions in intervention efficacy may be anticipated in other pediatric obesity treatment trials conducted during the COVID-19 pandemic. Many families that have struggled with managing their child’s weight during this period may need encouragement to continue engaging in structured weight management as society renormalizes.
METHODS

Analytic sample

Data for this analysis originated from an ongoing trial comparing home-based and clinic-based pediatric obesity treatment in lower-income families (ClinicalTrials.gov: NCT03195790). Both trial arms received the same 12-month, family-based pediatric obesity treatment and differed only in the location of treatment. This analysis pooled data across arms to examine changes in treatment efficacy related to the COVID-19 pandemic. The trial’s design paper includes methodological details and a description of the intervention (10).

Children aged 6 to 12 years with a BMI percentile ≥ 85 were recruited from pediatric primary care practices at major Chicago, Illinois medical centers. Eligible families had household incomes ≤ 200% of the federal poverty threshold. Participants in the analytic sample (n = 230) were a subset of trial participants (n = 269) who were randomized to treatment after August 2017 and completed at least one follow-up assessment before July 2021. COVID-19 stay-at-home orders at the study site (Chicago) took effect on March 16, 2020, and continued through mid-June 2021. Accordingly, children were categorized as participating before COVID-19 (randomized before March 16, 2019; n = 106) or during COVID-19 (randomized March 16, 2019, or later; n = 124). Given this cutoff date, the entire 12-month treatment period (and the follow-up assessment period) had concluded prior to the implementation of COVID-19 stay-at-home orders for all children categorized as participating before COVID-19. The Institutional Review Boards of Rush University Medical Center (protocol 15120306) and University of Illinois at Chicago (protocol 20170452) approved the study, and informed consent and child assent were obtained upon enrollment.

Intervention delivery before and during COVID-19

The Creating Healthy Environments for Chicago Kids (CHECK) intervention is a standard-of-care pediatric obesity treatment program with 18 in-person sessions and 12 monthly telephone support calls (10). Following the issuance of public health guidelines in March 2020, in-person intervention visits were held via videoconference or telephone. As restrictions eased, in-person visits resumed, with close adherence to COVID-19 transmission precautions (e.g., masking, social distancing, meeting outdoors when feasible). Monthly telephone support calls continued according to protocol throughout the pandemic.

Measures

Weight change

Change from baseline in BMI z score (ΔzBMI) was derived from objective height and weight measurements collected at baseline and at 3-, 6-, 9-, and 12-months post-randomization. In-person contact with participants was severely limited between March and mid-June 2020 because of stringent stay-at-home orders, including social distancing requirements and a prohibition against indoor gatherings. Research staff used various strategies to continue to collect objective height and weight measurements during this time, including collecting measurements outdoors or bringing sanitized, research-grade scales and stadiometers to participants’ homes and witnessing measurements taken by caregivers (either in-person or via videoconferencing) while maintaining social distancing.

Intervention receipt

The proportion of scheduled in-person intervention visits completed (of those due given their point in the intervention) was determined for each participant.

Study Importance

What is already known?

► Greater weight gain and engagement in obesogenic behaviors have been reported among children during the COVID-19 pandemic lockdown.

► There is limited data on how the pandemic has affected the efficacy of pediatric weight-management interventions.

What does this study add?

► Data from this clinical trial shows that the efficacy of a standard-of-care pediatric weight-management intervention was substantially reduced during the COVID-19 pandemic.

► Many children who received the intervention during the pandemic demonstrated significant weight gain despite receiving a 12-month weight-loss intervention.

How might these results change the direction of research or the focus of clinical practice?

► Children’s weight loss progress during the pandemic may not reflect their true potential for benefit, and families should be encouraged to continue structured weight-management efforts as society renormalizes.

► Other pediatric obesity treatment trials should report analyses characterizing change in intervention efficacy during the COVID-19 pandemic.
Demographic variables

Child age (derived from date of birth), gender, and ethnicity/race were reported by caregivers at baseline.

Data analysis

Mixed-effects regression was used to model multiple observations of ΔzBMI, nested within children, from the fixed effects of COVID-19 time period, assessment point (3, 6, 9, or 12 mo), and the interaction of COVID-19 time period and assessment point. Two a priori contrasts compared those participating before versus during COVID-19 at the 3-month and 12-month assessments, representing the end of intensive treatment and the end of intervention, respectively. Models included random intercepts and were adjusted for age (mean-centered), gender, race/ethnicity, and baseline zBMI (mean-centered) as potential confounders. The proportion of in-person visits completed during each 3-month follow-up interval, relative to the number scheduled in that same timeframe per trial protocol, was included as a time-varying covariate.

RESULTS

Characteristics of the analytic sample are shown in Table 1. Outcome data were available from 742 assessments, representing 87.9% retention overall. Owing to families being in various stages of follow-up, there were 208, 200, 164, and 170 observations available at 3, 6, 9, and 12 months, respectively.

A significant interaction was found between COVID-19 time period and assessment point in predicting ΔzBMI (χ² = 22.73, p < 0.0001). As depicted in Figure 1, participants receiving treatment before and during COVID-19 did not significantly differ on ΔzBMI at the 3-month assessment point (−0.05 vs. −0.01 ΔzBMI, respectively; χ² = 3.06, p = 0.08). However, children treated before COVID-19 generally maintained their initial weight loss, whereas children treated during COVID-19 subsequently gained weight for the remainder of follow-up. At the final 12-month assessment, ΔzBMI was −0.06 among children treated before COVID-19 compared with a net gain of 0.11 ΔzBMI among children treated during COVID-19 (χ² = 34.99, p < 0.0001). Age (estimate = 0.002, p = 0.68), female gender (estimate = 0.004, p = 0.85), baseline zBMI (estimate = −0.04, p = 0.10), and race (estimate = 3.02, p = 0.22) were not associated with ΔzBMI. The proportion of completed treatment sessions did not significantly differ between children treated before and during COVID-19 (60.4% vs. 55.7%, respectively; t² = 1.05, p = 0.30), and session completion was not associated with ΔzBMI (estimate = −0.03, p = 0.36) when included in the model.

DISCUSSION

The efficacy of structured, family-based pediatric obesity treatment was significantly attenuated during the COVID-19 pandemic among low-income, urban, racially diverse children. Children who received treatment prior to the pandemic demonstrated an initial weight loss that was largely maintained across 12 months, whereas children treated during the pandemic showed similar initial weight loss but subsequently gained weight until reaching a net ΔzBMI gain well above baseline.

The reduction in treatment efficacy was not attributable to decreased intervention session completion. Considering reports of COVID-19-related weight gain in nontreated adults and children (3, 8, 11, 12), the attenuation in treatment efficacy likely reflects the broader influence of COVID-19 pandemic stay-at-home orders on

| TABLE 1 Characteristics of children whose participation in pediatric obesity treatment occurred before or during the COVID-19 pandemic |
|---------------------------------------------------------------|
| **Total (n = 230)** | **Before COVID-19 (n = 106)** | **During COVID-19 (n = 124)** |
| Age, y, mean (SD) | 9.7 (1.9) | 9.2 (1.8) | 10.0 (1.9) |
| Baseline ΔzBMI, mean (SD) | 2.1 (0.5) | 2.1 (0.5) | 2.1 (0.5) |
| Baseline weight status, n (%) |  |  |  |
| Overweight | 46 (20.0) | 23 (21.7) | 23 (18.6) |
| Obesity | 184 (80.0) | 83 (78.3) | 101 (81.5) |
| Female gender, n (%) | 114 (49.6) | 59 (55.7) | 55 (44.4) |
| Race/ethnicity, n (%) |  |  |  |
| Black | 106 (46.1) | 66 (62.3) | 40 (32.3) |
| Hispanic | 113 (49.1) | 35 (33.0) | 78 (62.9) |
| Non-Hispanic White/other | 11 (4.8) | 5 (4.7) | 6 (4.8) |

*Before COVID-19* participants were randomized to treatment before March 16, 2019, at least 12 months prior to the implementation of pandemic public health measures. **During COVID-19** participants were randomized on March 16, 2019, or later.

ΔzBMI = BMI z score for age and sex;

Overweight was defined as BMI percentile 85.0 to 94.99. Obesity was defined as BMI percentile ≥ 95.0.
household routines and children's obesogenic behaviors. We cannot rule out the possibility that treatment efficacy was affected by COVID-19-related changes in the modality of intervention delivery, such as conducting sessions via videoconferencing. However, this is unlikely, as telephone-based and in-person interventions typically produce comparable weight-loss benefits (13-15). Further investigation into the mechanisms that explain the attenuated intervention efficacy during COVID-19 is warranted and may yield insights that remain relevant beyond the pandemic.

A key takeaway from this study is that a family's (lack of) success in managing their child's weight during the pandemic does not necessarily represent their true potential to be successful within a structured intervention. It may be important to normalize the experience of families who struggled to lose weight during the pandemic and encourage continued engagement in structured weight-loss programs. The present findings also suggest that normalization of society (school re-openings, resumption of youth sports and activities) may be a necessary condition for successful weight management in children.

The present findings also have implications for the interpretation of ongoing pediatric obesity treatment trials. As of July 2021, there were over 120 active clinical trials focused on pediatric obesity listed in ClinicalTrials.gov. In addition to other statistical procedures (16), investigators should conduct and report supplementary analyses that characterize changes in treatment efficacy associated with the pandemic.

Several strengths and limitations of the study are noteworthy. Given its timeline, the parent trial was uniquely positioned to examine changes in pediatric obesity treatment efficacy following the COVID-19 lockdown. The study focused on low-income children aged 6 to 12 who were predominantly of a racial minority, a group with a high burden of pediatric obesity (17) and poorer engagement and outcomes in weight-management interventions (18,19). However, findings may not generalize to other populations, and the sample’s composition did not enable comparisons with higher-socioeconomic status or nonminority children.

CONCLUSION

The efficacy of pediatric obesity treatment was markedly attenuated during the COVID-19 pandemic. Although this effect is presumably attributable to the impact of stay-at-home orders on children's obesogenic behaviors, the specific contextual and behavioral mechanisms that impeded weight loss during the pandemic deserve further examination. The impact of the pandemic on pediatric obesity treatment efficacy should be considered and addressed when interpreting clinical research conducted during this time and when developing treatment plans for children with overweight or obesity.

ACKNOWLEDGMENTS

We are grateful for the assistance of Dr. Lauren Bradley, Michelle Li, Eileen Cameron, Katerina Newman, Serina Sylvestry, Kelly Wagner, Katey Feit, Melanie Battaglia, Tami Olinger, Barb Mascitti, Elizabeth Avery, Dan Lindich, and Alyssa Cho.

CONFLICT OF INTEREST

The authors declared no conflict of interest.

CLINICAL TRIAL REGISTRATION

ClinicalTrials.gov identifier NCT03195790.

ORCID

Bradley M. Appelhans https://orcid.org/0000-0002-5195-802X
Simone A. French https://orcid.org/0000-0003-3413-5985

REFERENCES

1. Weaver RG, Armstrong B, Hunt E, et al. The impact of summer vacation on children’s obesogenic behaviors and body mass index: a natural experiment. Int J Behav Nutr Phys Act. 2020;17:153. doi:10.1186/s12966-020-01052-0
2. Weaver RG, Beets MW, Brazendale K, Brusseau TA. Summer weight gain and fitness loss: causes and potential solutions. Am J Lifestyle Med. 2019;13:116-128.
3. Stockwell S, Trott M, Tully M, et al. Changes in physical activity and sedentary behaviours from before to during the COVID-19 pandemic lockdown: a systematic review. BMJ Open Sport Exerc Med. 2021;7:e000960. doi:10.1136/bmjsem-2020-000960
4. Yomoda K, Kurita S. Influence of social distancing during the COVID-19 pandemic on physical activity in children: a scoping review of the literature. J Exerc Sci Fit. 2021;19:203.
5. Kaditis AG, Ohler A, Gileles-Hillel A, et al. Effects of the COVID-19 lockdown on sleep duration in children and adolescents: a survey across different continents. Pediatr Pulmonol. 2021;56:2265-2273.
6. Neshteruk CD, Zizzi A, Suarez L, et al. Weight-related behaviors of children with obesity during the COVID-19 pandemic. Child Obes. 2021;17:371-378.
7. Philippe K, Chabanet C, Issanchou S, et al. Child eating behaviors, parental feeding practices and food shopping motivations during the COVID-19 lockdown in France: (how) did they change? Child Obes. 2021;161:105132. doi:10.1016/j.appet.2021.105132
8. Weaver RG, Hunt ET, Armstrong B, et al. COVID-19 leads to accelerated increases in children’s BMI z-score gain: an interrupted time-series study. *Am J Prev Med*. 2021;61:e161-e169.

9. Janicke DM, Steele RG, Gayes LA, et al. Systematic review and meta-analysis of comprehensive behavioral family lifestyle interventions addressing pediatric obesity. *J Pediatr Psychol*. 2014;39:809-825.

10. Appelhans BM, French SA, Bradley LE, Lui K, Janssen I, Richardson D. CHECK: a randomized trial evaluating the efficacy and cost-effectiveness of home visitation in pediatric weight loss treatment. *Contemp Clin Trials*. 2020;88:105891. doi:10.1016/j.cct.2019.105891

11. Bakaloudi DR, Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Chouridakis M. Impact of the first COVID-19 lockdown on body weight: a combined systematic review and a meta-analysis [published online April 13, 2021]. *Clin Nutr*. doi:10.1016/j.clnu.2021.04.015

12. Bennett G, Young E, Butler I, Coe S. The impact of lockdown during the COVID-19 outbreak on dietary habits in various population groups: a scoping review. *Front Nutr*. 2021;8:626432. doi:10.3389/fnut.2021.626432

13. Bohlin A, Hagman E, Klaesson S, Danielsson P. Childhood obesity treatment: telephone coaching is as good as usual care in maintaining weight loss - a randomized controlled trial. *Clin Obes*. 2017;7:199-205.

14. Befort CA, VanWormer JJ, Desouza C, et al. Effect of behavioral therapy with in-clinic or telephone group visits vs in-clinic individual visits on weight loss among patients with obesity in rural clinical practice: a randomized clinical trial. *JAMA*. 2021;325:363-372.

15. Perri MG, Limacher MC, Durning PE, et al. Extended-care programs for weight management in rural communities: the treatment of obesity in underserved rural settings (TOURS) randomized trial. *Arch Intern Med*. 2008;168:2347-2354.

16. Meyer RD, Ratitch B, Wolbers M, et al. Statistical issues and recommendations for clinical trials conducted during the COVID-19 pandemic. *Stat Biopharm Res*. 2020;12:399-411.

17. Ogden CL, Carroll MD, Fakhouri TH, et al. Prevalence of obesity among youths by household income and education level of head of household—United States 2011-2014. *MMWR Morb Mortal Wkly Rep*. 2018;67:186-189.

18. Davison GM, Fowler LA, Ramel M, et al. Racial and socioeconomic disparities in the efficacy of a family-based treatment programme for paediatric obesity. *Ped Obes*. 2021;16:e12792. doi:10.1111/ijpo.12792

19. Ligthart KAM, Buitendijk L, Koes BW, van Middelkoop M. The association between ethnicity, socioeconomic status and compliance to pediatric weight-management interventions - a systematic review. *Obes Res Clin Pract*. 2017;11(Suppl 1):1-51.

How to cite this article: Appelhans BM, French SA, Martin MA, Lui K, Janssen I. Attenuated efficacy of pediatric obesity treatment during the COVID-19 pandemic. *Obesity (Silver Spring)*. 2022;30:45–49. doi:10.1002/oby.23313